Chiasma Raises $44 Million

Chiasma Inc., a biotech company focused on enhanced oral delivery of proteins and small molecules, has raised $44 million in Series C funding. MPM Capital led the deal, and was joined by Arch Venture Partners and return backers Ofer Hi-Tech Group and F-2 Ventures. The company will move its headquarters from Israel to Boston, but will maintain a research subsidiary in Jerusalem.